• Publications
  • Influence
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
ContextThe α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel α4β2 nAChR partial agonist, may beExpand
  • 1,155
  • 61
  • PDF
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
ContextVarenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewardingExpand
  • 1,243
  • 52
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
CONTEXT The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partialExpand
  • 478
  • 52
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
CONTEXT Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing theExpand
  • 436
  • 42
Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation
Most smokers repeatedly fail in their attempts to stop smoking because of the addictive nature of the nicotine in tobacco products. Nicotine dependence is probably mediated through the activation ofExpand
  • 185
  • 25
  • PDF
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
CONTEXT The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacologicalExpand
  • 609
  • 23
  • PDF
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.
Most smokers repeatedly fail in their attempts to stop smoking because of the addictive nature of the nicotine in tobacco products. Nicotine dependence is probably mediated through the activation ofExpand
  • 103
  • 20
Efficacy of Varenicline , an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist , vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
CIGARETTE SMOKING REMAINS the leading preventable cause of illness and premature death in the United States, claiming an estimated 438 000 lives per year. Research over the past 3 decades hasExpand
  • 270
  • 19
  • PDF
Attention Deficit Hyperactivity Disorder in Children and Adolescents Following Traumatic Brain Injury
To better characterize pediatric psychopathology after neurological insult, secondary attention deficit hyperactivity disorder (SADHD)-or ADHD that develops after traumatic brain injury (TBI)-and itsExpand
  • 178
  • 16
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.
The pharmacological properties and pharmacokinetic profile of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline provide an advantageous combination of free brainExpand
  • 107
  • 12